Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Sponsor
Women's Hospital School Of Medicine Zhejiang University
Study ID
NCT07167160
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab combined with chemotherapy — DRUG
    Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery

Study Details

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Key Dates

Start date
Mar 10, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2029

Study Design

Enrollment
59 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: chemotherapy group

Primary Outcome Measure

3-year disease-free survival rate [ Time Frame: from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months ]

Related Studies